Genome-based management for patients with unclear genetic diseases

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This project aims to enroll approximately 12,000 patients who have unclear molecular causes of their diseases or suspected genetic causes without prior detailed molecular analysis. The study introduces a novel approach by integrating genomic health concepts into clinical care, utilizing Whole Genome Sequencing (WGS) as a first-line diagnostic tool for rare diseases and familial cancer syndromes. The methodology involves a personalized medicine framework that emphasizes predictive and preventive strategies within a well-established healthcare system, supported by decentralized Disease Analysing Task Forces (DATF).

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Unclear molecular cause of the disease
* Suspected genetic cause of the disease

Exclusion Criteria:

* Missing informed consent of the patient and if applicable the legal representative
* Previously performed WES or panel analysis

Where it's running

• University Hospital Tübingen
  Tübingen, Germany Recruiting

Study contacts

• Study coordinator: Olaf Rieß, Prof. Dr.
• Email: olaf.riess@med.uni-tuebingen.de
• Phone: +49 7071 29

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Investigating genetic causes in twins with different health outcomes

  This study is trying to find out what genetic differences might explain why one twin is healthy while the other has an undiagnosed disease.

  Recruiting University Hospital Tuebingen · Tübingen · NCT04046796

• Sirolimus for ApoE4 Carriers: Testing Brain Blood Flow in Women 45-65

  Researchers will test whether sirolimus can improve brain blood flow in healthy ApoE4-positive women ages 45 to 65 compared with a placebo.

  Recruiting Phase 1 University of Missouri-Columbia · Columbia, Missouri · NCT07728175

• AI-assisted Rare-Disease Diagnosis

  A multicenter randomized test to see if an AI diagnostic tool can help doctors make faster, more accurate rare-disease diagnoses for patients with unresolved symptoms.

  Recruiting at 3 sites Peking Union Medical College Hospital · Cangzhou and 11 other locations · NCT07650799

• Socio‑professional inclusion for young people (15–25) with childhood-onset rare genetic disabilities

  This project will try to see what makes it hard for 15–25‑year‑olds with childhood-onset rare genetic conditions to access higher education, internships, or work.

  Recruiting Imagine Institute · Paris, Île-de-France Region · NCT07527624

• Treatment approaches for AChR-antibody positive generalized myasthenia gravis in Russia.

  This project will look at which treatments adults in Russia with AChR-antibody positive generalized myasthenia gravis receive and how their symptoms and hospitalizations change over time.

  Recruiting at 7 sites AstraZeneca · Kazan' and 6 other locations · NCT07247279

• Long-term outcomes for people with immune TTP in the French national TMA cohort

  This project uses past medical records to see long-term health outcomes and complications in people in France who had immune thrombotic thrombocytopenic purpura (iTTP).

  Recruiting Assistance Publique - Hôpitaux de Paris · Paris · NCT07205861

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.